Quadria Capital
Quadria Capital is a Singapore-based private equity firm managing over US$4.2 billion in healthcare-focused funds (latest Fund III at US$1.07B) and a 29-company portfolio across South, Southeast Asia, and now the GCC, partnering with healthcare operators to build regional leaders in delivery, life sciences, medtech, and digital health.
- Company typePrivate
- Founded2012
- HeadquartersSingapore, Singapore
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Quadria Capital does
Quadria Capital is a Singapore-headquartered private equity firm founded in 2012 that manages capital exclusively for healthcare investments across South and Southeast Asia. The firm operates under the legal entity Quadria Capital Investment Management Pte Ltd, regulated by the Monetary Authority of Singapore, with additional offices in New Delhi (South Asia hub), Ho Chi Minh City, Jakarta, and a newly opened Dubai office for GCC expansion. The firm manages over US$4.2 billion in assets across multiple funds, with its third fund (Fund III) closed at US$1.07 billion in 2025 — the largest healthcare-focused fundraise in the region per the Singapore Venture & Private Capital Association. The portfolio comprises 29 investments across 8 markets spanning four healthcare verticals: Healthcare Delivery (NephroPlus dialysis network, Maxivision Eye Hospitals, Tam Tri Medical hospitals, AIG Hospitals), Life Sciences (Aragen Life Sciences CRDMO, Encube Ethicals topical drugs, Apex Healthcare pharmaceuticals), Medical Technology (Straits Orthopaedics implants CDMO), and Associated Healthcare Services (MediBuddy digital health, Nobel Hygiene).
Quadria's revenue model is conventional institutional fund management — earning management fees on committed/invested AUM plus carried interest on investment returns above hurdle rates. The firm supplements this with non-traditional capital instruments including a US$200 million social loan (Asia's first, closed in 2023) to fund healthcare, pharmaceutical, and diagnostic investments. Its underlying 'technology' is a proprietary investment methodology rather than software: a healthcare-specific due diligence framework, a defined value creation methodology with dedicated operating partners and a Value Optimisation Board, and a proprietary 3-tiered Impact Management and Measurement Framework (Impact Thesis, ABC Investment Strategy, ESG evaluation process) verified independently by BlueMark and aligned with UN PRI and OPIM principles.
The firm serves a dual customer base: institutional limited partners (sovereign wealth funds, development finance institutions including Proparco, pension funds, family offices) for capital raising, and healthcare companies and entrepreneurs for investment deployment. Go-to-market is relationship-driven and proprietary, leveraging deep local networks for deal origination at favorable valuations, dedicated operational support post-investment, and active portfolio synergies across companies. Recent notable transactions include the US$470 million take-private of Malaysia's Apex Healthcare (2026, largest healthcare buyout in Southeast Asia in five years), the partial IPO exit from NephroPlus (December 2025), and a US$100 million co-investment with Goldman Sachs in Aragen Life Sciences for Indian capacity expansion.
Quadria Capital firmographics
Firmographics- Name
- Quadria Capital
- Legal name
- Quadria Capital Investment Management Pte Ltd
- Website
- http://quadriacapital.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Quadria Capital is a Singapore-based private equity firm managing over US$4.2 billion in healthcare-focused funds (latest Fund III at US$1.07B) and a 29-company portfolio across South, Southeast Asia, and now the GCC, partnering with healthcare operators to build regional leaders in delivery, life sciences, medtech, and digital health.
- Ownership category
- akta.pro rank
Quadria Capital industry classification
Industry- Product category
- Healthcare Private Equity
- NAICS
- Portfolio Management and Investment Advice (52394), Other Financial Vehicles (525990)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Venture Capital Fund-of-Funds / Multi-Manager Platforms (FSANAAAJ)
- akta.pro secondary industry
- Endowments (Universities, Foundations, Nonprofits) (FSAAAGAC)
Keywords
Where Quadria Capital is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices5 records
Markets served
Quadria Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Private Equity Fund Management: Quadria Capital generates returns by managing private equity funds investing in healthcare companies across South and Southeast Asia. The firm earns management fees on assets under management and performance-based carried interest on investment returns, with a focus on delivering superior financial returns and meaningful social impact. The firm closed Fund III at $1.07 billion.
- Social Loan Origination: Quadria Capital closed Asia's first social loan of up to $200 million to fund healthcare, pharmaceutical, and diagnostic investments in South and Southeast Asia, aimed at improving access to healthcare and essential services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Institutional Fund Investment (Fund III) |
Go-to-market motion3 records
Distribution channels2 records
Marketing channels5 records
Quadria Capital product offering
Product offeringCore offering
Quadria Capital is a healthcare-focused private equity firm that raises and manages investment funds from institutional investors to acquire and partner with large, scalable healthcare companies across South and Southeast Asia. The firm provides capital, strategic guidance, and operational support through dedicated Operating Partners and a Value Optimisation team to build regional healthcare leaders, generating returns through management fees on assets under management and performance-based carried interest.
Product overview
Quadria Capital is a healthcare-focused private equity firm that operates as a fund manager and investment platform rather than a traditional product company. The firm's offering consists of investment management services and a portfolio of healthcare companies across South and Southeast Asia. The portfolio spans four main sectors: Healthcare Delivery (dialysis networks, eye care hospitals), Life Sciences (pharmaceuticals, CRDMO services, topical drugs), Medical Devices (orthopaedic manufacturing), and Associated Healthcare Services (digital health platforms, hygiene products). Key portfolio companies include NephroPlus (dialysis), Maxivision (eye care), MediBuddy (digital health), Encube Ethicals (topical drugs), Nobel Hygiene (personal hygiene), Apex Healthcare (pharmaceutical distribution), Aragen Life Sciences (contract research/manufacturing), and Straits Orthopaedics (medical devices).
Differentiator
Problem solved
Functional benefit
Brands
- HealthQuad: India's largest growth venture firm focused on investing in new-age, transformative healthcare models, co-founded by Quadria's Managing Partner Abrar Mir
- Quadria Capital Fund III LP
Products and services
- Quadria Capital Fund III LP
- Value Optimisation Services
Quantifiable outcome
- NephroPlus IPO listed at 7% premium over issue price of INR 490, subscribed 14 times overall and 27 times by Qualified Institutional Buyers
- +6 more outcomes
Companies that use Quadria Capital
Customer profileNamed customers8 records
Ideal customer profiles2 records
Quadria Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Quadria Capital partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- BlueMarkcoreBlueMark, a specialist verification provider for impact investing, conducted independent assessment of Quadria Capital Fund III's impact management measurement framework and issued verification statements for 2025 and 2026, affirming the effectiveness of Quadria's IMM framework.
- Singapore Venture & Private Capital Association (SVCA)coreSVCA awarded Quadria Capital Fundraise of the Year 2025 for raising Fund III at US$1.07 billion, exceeding its $800 million target. The firm also won SVCA's Private Equity Deal of the Year for two consecutive years.
- Straits Orthopaedics (Co-investment with Founder)coreQuadria Capital acquired a majority stake in Straits Orthopaedics, a Penang-based medical device manufacturer, from its founder Mr. TH Su and Apex Healthcare Bhd. The deal included re-investments by the founder and Apex Healthcare Bhd., with Mr. Su reappointed as CEO to lead future growth. The partnership aims to strengthen the company's market position as a global orthopaedic manufacturing leader.
- United Nations Principles for Responsible Investment (UN PRI)coreQuadria Capital is a signatory to UN PRI and achieved top ratings in its inaugural assessment. The firm is aligned with all UN PRI principles for responsible investment.
- Operating Principles for Impact Management (OPIM)coreQuadria Capital is a signatory to OPIM, reaffirming alignment with all nine principles. Quadria's Impact Management Framework brings to life its Responsible Investment Policy.
- Aragen Life SciencescoreQuadria Capital invested $100 million in Aragen Life Sciences for domestic capacity expansion in India. Aragen serves as a trusted R&D and manufacturing partner to the global life sciences industry, servicing over 400 customers across large pharma, biotech, agrochemical, and animal health industries.
Scale indicators15 records
Recent moves8 records
Expansion highlights6 records
Quadria Capital competitors and assessment
Company assessmentDirect peers
- TVM Capital Healthcare: Healthcare-focused private equity firm investing across Asia and the Middle East with dedicated operating partners and a regional value-creation approach. Direct peer to Quadria given overlapping healthcare-only thesis, geographic footprint (MENA + Asia), and similar cheque sizes in growth-stage healthcare.
- Olympus Capital Asia: Asia-focused private equity firm with a strong healthcare and consumer orientation, targeting control and growth investments across India, China, and Southeast Asia. Direct peer to Quadria based on shared regional remit, healthcare sector focus, and growth-equity mandate.
- Everlife Asia Partners: Southeast Asia-focused healthcare distribution and investment platform backed by founding investors including Quadria's co-founder Abrar Mir. Direct peer in the Asia healthcare distribution and specialty investing space with comparable therapeutic and geographic coverage.
- Navis Capital Partners: One of the largest dedicated Southeast Asia-focused private equity firms, investing across healthcare, consumer, and industrials with a strong operating-partner value-creation model. Direct peer based on shared Southeast Asia healthcare exposure and growth-equity approach.
- Creador: Southeast and South Asia-focused private equity firm investing in growth-stage consumer, financial services, and healthcare businesses. Direct peer given overlapping South/Southeast Asia focus, growth-stage mandate, and similar founder-driven value-creation orientation.
- Affirma Capital (formerly Standard Chartered PE): Pan-Asia mid-market private equity firm with sector coverage spanning healthcare, consumer, and business services across India, Southeast Asia, and Greater China. Direct peer given shared Asia growth-equity mandate and comparable fund size.
- AID Partners Capital: Hong Kong-based private equity firm focused on healthcare and consumer investments across Greater China, Southeast Asia, and India. Direct peer based on Asia healthcare sector focus and growth-to-control investment approach.
Broad incumbents
- Baring Private Equity Asia (EQT): Large pan-Asia private equity platform (now part of EQT) with broad sector coverage including significant healthcare exposure. Broader incumbent peer given much larger fund sizes, broader sector mandate, and global LP base, but competes for similar control deals in Asia healthcare.
- KKR Asia Healthcare: Global private equity firm with an established Asia healthcare strategy spanning delivery, pharma services, and medtech. Broader incumbent peer given mega-fund scale, global LP base, and growing competition for control healthcare assets in India and Southeast Asia.
- Asia Healthcare Fund (Advent International): Global private equity firm with dedicated Asia healthcare investing across pharmaceuticals, medtech, and healthcare services. Broader incumbent peer given much larger fund sizes and global operating resources, but comparable in Asian healthcare sector focus and growth-to-control mandate.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Quadria Capital social profiles
Digital presenceQuadria Capital compliance and trust
Trust signalCompliance4 records
Quadria Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
Quadria Capital leadership team
Management profileNumber of profiles
Profiles12 records
Quadria Capital subsidiaries and ownership
Company hierarchySubsidiaries10 records
Quadria Capital funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Quadria Capital M&A and investment
M&A and investmentM&A2 records
Investments24 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Quadria Capital
What does Quadria Capital do?
Quadria Capital is a healthcare-focused private equity firm that raises and manages investment funds from institutional investors to acquire and partner with large, scalable healthcare companies across South and Southeast Asia. The firm provides capital, strategic guidance, and operational support through dedicated Operating Partners and a Value Optimisation team to build regional healthcare leaders, generating returns through management fees on assets under management and performance-based carried interest.
Is Quadria Capital a public or private company?
Quadria Capital is a private company. It is classified as venture growth investor backed and is currently operating.
When was Quadria Capital founded?
Quadria Capital was founded in 2012. It employs 11 to 50 people.
Where is Quadria Capital based?
Quadria Capital is headquartered in Singapore, Singapore, in the Asia region.
How does Quadria Capital make money?
Two revenue lines are on record. Private Equity Fund Management is the primary driver. The others are social Loan Origination.
Who are Quadria Capital's main competitors?
Direct peers on record are TVM Capital Healthcare, Olympus Capital Asia, Everlife Asia Partners, Navis Capital Partners, Creador, Affirma Capital (formerly Standard Chartered PE) and AID Partners Capital. Broad incumbents are Baring Private Equity Asia (EQT), KKR Asia Healthcare and Asia Healthcare Fund (Advent International).
Does Quadria Capital have an API?
No public API is recorded for Quadria Capital.
What industry is Quadria Capital in?
Quadria Capital's product category is Healthcare Private Equity. Its primary akta.pro industry code is FSANAAAJ, Venture Capital Fund-of-Funds / Multi-Manager Platforms, with a secondary code of FSAAAGAC, Endowments (Universities, Foundations, Nonprofits). Its NAICS code is 52394 and its SIC code is 6282.